|
21 Jan 2021 |
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
|
|
20 Jan 2021 |
Turnstone Biologics Acquires Novel Cell Therapy Platform
|
|
18 Jan 2021 |
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
|
|
15 Jan 2021 |
Ubiquigent and the University of York Awarded a Grant to Explore the Potential of Deubiquitylase (DUB) Enzyme Inhibitors to Address Neglected Tropical Diseases
|
|
15 Jan 2021 |
Syntekabio Signs Joint Development Agreement with Hanmi Science
|
|
13 Jan 2021 |
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
|
|
13 Jan 2021 |
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
|
|
13 Jan 2021 |
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
|
|
12 Jan 2021 |
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
|
|
12 Jan 2021 |
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
|
|
11 Jan 2021 |
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs
|
|
11 Jan 2021 |
Eligo Bioscience inks deal with GSK potentially worth up to $224 million
|
|
10 Jan 2021 |
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
|
|
08 Jan 2021 |
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
|
|
08 Jan 2021 |
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
|
|
07 Jan 2021 |
Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies
|
|
07 Jan 2021 |
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
|
|
07 Jan 2021 |
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
|
|
06 Jan 2021 |
Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy
|
|
06 Jan 2021 |
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
|
|
30 Dec 2020 |
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
|
|
23 Dec 2020 |
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
|
|
23 Dec 2020 |
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
|
|
23 Dec 2020 |
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
|
|
22 Dec 2020 |
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
|
